Yuri Jeong1, Jin-Hong Park2, Young-Joo Lee3, Kwang-Min Park3, Shin Hwang3, Heung-Moon Chang4, Kyu-Pyo Kim4, Sang Min Yoon1, Nuri Hyun Jung1, Jong Hoon Kim1. 1. Department of Radiation Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea. 2. Department of Radiation Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea jpark@amc.seoul.kr. 3. Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea. 4. Department of Medical Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
Abstract
AIM: To evaluate the results of postoperative radiotherapy (PORT) and to identify prognostic factors for gallbladder cancer (GBC). PATIENTS AND METHODS: We retrospectively analyzed 86 patients with GBC who underwent potentially curative surgical resection and PORT between November 1993 and December 2009. All patients received three-dimensional conformal radiotherapy and 61 patients (71%) had concurrent chemotherapy. Survival outcomes including locoregional control (LRC), disease-free survival (DFS) and overall survival (OS) rates were analyzed. RESULTS: The median follow-up period was 83 months for surviving patients. The 5-year OS, DFS and LRC rates were 42%, 36% and 73%, respectively. Isolated locoregional recurrence as first failure occurred in seven patients (8%). On multivariate analysis, the postoperative carbohydrate antigen 19-9 (CA 19-9) level was a significant prognostic factor for LRC, DFS and OS. CONCLUSION: Adjuvant radiotherapy might be an effective treatment in terms of LRC in GBC. Postoperative CA 19-9 might be useful as a surrogate marker for survival. Copyright
AIM: To evaluate the results of postoperative radiotherapy (PORT) and to identify prognostic factors for gallbladder cancer (GBC). PATIENTS AND METHODS: We retrospectively analyzed 86 patients with GBC who underwent potentially curative surgical resection and PORT between November 1993 and December 2009. All patients received three-dimensional conformal radiotherapy and 61 patients (71%) had concurrent chemotherapy. Survival outcomes including locoregional control (LRC), disease-free survival (DFS) and overall survival (OS) rates were analyzed. RESULTS: The median follow-up period was 83 months for surviving patients. The 5-year OS, DFS and LRC rates were 42%, 36% and 73%, respectively. Isolated locoregional recurrence as first failure occurred in seven patients (8%). On multivariate analysis, the postoperative carbohydrate antigen 19-9 (CA 19-9) level was a significant prognostic factor for LRC, DFS and OS. CONCLUSION: Adjuvant radiotherapy might be an effective treatment in terms of LRC in GBC. Postoperative CA 19-9 might be useful as a surrogate marker for survival. Copyright
Authors: Richard S Hoehn; Koffi Wima; Audrey E Ertel; Alexandra Meier; Syed A Ahmad; Shimul A Shah; Daniel E Abbott Journal: J Gastrointest Surg Date: 2015-08-21 Impact factor: 3.452
Authors: Jae Woo Lee; Yong-Tae Kim; Sang Hyub Lee; Jun Hyuk Son; Jin Woo Kang; Ji Kon Ryu; Dong Kee Jang; Woo Hyun Paik; Ban Seok Lee Journal: Gut Liver Date: 2018-01-15 Impact factor: 4.519